ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Abstract Number: 0069

All-trans Retinoic Acid (atRA) Enhances FoxP3 Protein Stability Under Inflammatory Conditions Through Altering the FoxP3 Protein-interactome
Abstract Number: 0070

Activation of Joint CD8+ TRM Localize Autoantibody Mediated Arthritis
Abstract Number: 0071

Sex Based Differences in Morphological and Functional Niches of the Human Thymus, Identified by Non-supervised Spatial Transcriptomic Profiling, May Underlie Sex Bias in Autoimmune Disease
Abstract Number: 0072

Circulating T-cell Immunosenescence Is High in Patients with Immune-Mediated Inflammatory Diseases (IMIDs) and Is Associated with Interferons
Abstract Number: 0073

PD-1hi Cells Are Highly Present in the Rheumatoid Joint, and Express Regulatory Capacities
Abstract Number: 0074

Distinct PD-1 Receptor Engagement Leads to Different Pharmacodynamic Effects
Abstract Number: 0075

Proteomic, Transcriptomic, and T-Cell Receptor (TCR) Profiling of Synovial Integrin-Expressing (InEx) T Cells in Axial Spondyloarthritis (axSpA)
Abstract Number: 0076

Characterizing GMCSF Producing T-cells in Rheumatoid Arthritis and Effect of Methotrexate on Them
Abstract Number: 0077

Circulating CD4+CXCR5-PD-1hiICOS+ Cells Are Elevated in Patients with Newly Diagnosed Giant Cell Arteritis and Associate with the Clinical Outcome
Abstract Number: 0078

Circulating CD4+CXCR5+PD-1hi Follicular Helper T Cells Are Elevated in Patients with Rheumatoid Arthritis and Predict Treatment Response to Abatacept or TNF Blockers
Abstract Number: 0079

CD4 T Cell Repertoire Features in RA Patients with High-risk HLA-DRB1 Alleles
Abstract Number: 0080

Pharmacological Inhibition of PRMT5 Demonstrates Broad Efficacy in Multiple Preclinical Models of Autoimmunity and Inflammation by Suppressing Th1, Th17 and TNF-Mediated Inflammatory Responses
Abstract Number: 0081

RA Disease Activity Influence the Frequency and Phenotype of Citrulline Reactive CD4 T Cells in DRB1*04:04 ACPA+ RA Patients
Abstract Number: 0082

A VAV1-Directed Molecular Glue Degrader, MRT-6160, Reduces Joint Inflammation in a Collagen-Induced Arthritis Autoimmune Disease Model
Abstract Number: 0083

Expression of mRNA Vaccine Antigen in Hematopoietic Cells Is Necessary for Induction of Optimal Vaccine-Specific CD4+ T Cell Responses

« Previous Page
1
…
6
7
8
9
10
…
177
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].